Stock FDMT 4D MOLECULAR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company 4D Molecular Therapeutics, Inc.

Equities

FDMT

US35104E1001

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:03 2024-05-31 pm EDT 		5-day change 1st Jan Change
24 USD -2.56% Intraday chart for 4D Molecular Therapeutics, Inc. -4.57% +18.46%
May. 15 Transcript : 4D Molecular Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 03:40 PM
May. 09 4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Number of employees: 171

Sales per Business

USD in Million2022Weight2023Weight Delta
Gene Therapeutic Products
100.0 %
3 100.0 % 21 100.0 % +562.29%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
97.3 %
0 1.1 % 20 97.3 % +57,488.57%
Netherlands
2.7 %
3 98.9 % 1 2.7 % -81.67%

Managers

Managers TitleAgeSince
Theresa Janke FOU
 Founder 49 13-09-11
David Kirn FOU
 Founder 62 13-09-11
Uneek Mehra DFI
 Director of Finance/CFO 51 23-09-11
Fariborz Kamal PSD
 President 61 18-09-30
Robert Kim CTO
 Chief Tech/Sci/R&D Officer 63 22-09-30
Noriyuki Kasahara CTO
 Chief Tech/Sci/R&D Officer 62 22-09-22
Julian Pei IRC
 Investor Relations Contact - -
Scott Bizily HRO
 Human Resources Officer 52 21-08-31
An Song PRN
 Corporate Officer/Principal - 21-08-31

Members of the board

Members of the board TitleAgeSince
John Milligan CHM
 Chairman 63 20-07-31
Susannah Gray BRD
 Director/Board Member 63 20-06-30
Charles Theuer BRD
 Director/Board Member 60 15-12-31
David Kirn FOU
 Founder 62 13-09-11
Jacob Chacko BRD
 Director/Board Member 45 19-02-28
Shawn Tomasello BRD
 Director/Board Member 65 20-11-17
Nancy Miller-Rich BRD
 Director/Board Member 65 20-11-17
Noriyuki Kasahara CTO
 Chief Tech/Sci/R&D Officer 62 22-09-22

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 51,703,412 49,347,153 ( 95.44 %) 0 95.44 %

Shareholders

NameEquities%Valuation
RA Capital Management LP
9.874 %
5,051,511 9.874 % 119 M $
Venrock Associates
8.601 %
4,400,000 8.601 % 104 M $
BVF, Inc.
7.667 %
3,922,413 7.667 % 92 M $
BlackRock Advisors LLC
7.507 %
3,840,444 7.507 % 90 M $
Janus Henderson Investors US LLC
6.250 %
3,197,444 6.250 % 75 M $
Goldman Sachs Asset Management LP
5.977 %
3,057,849 5.977 % 72 M $
Deep Track Capital LP
5.932 %
3,034,453 5.932 % 71 M $
Viking Global Investors LP
5.737 %
2,934,914 5.737 % 69 M $
Vanguard Fiduciary Trust Co.
4.574 %
2,339,943 4.574 % 55 M $
STATE STREET CORPORATION
4.258 %
2,178,230 4.258 % 51 M $

Company contact information

4D Molecular Therapeutics, Inc.

5858 Horton Street Suite 455

94608, Emeryville

+

http://www.4dmoleculartherapeutics.com
address 4D Molecular Therapeutics, Inc.(FDMT)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for 4D Molecular Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
23.97 USD
Average target price
52.3 USD
Spread / Average Target
+118.19%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
4D MOLECULAR THERAPEUTICS, INC. Stock 4D Molecular Therapeutics, Inc.
+18.46% 1.24B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. FDMT Stock
  4. Company 4D Molecular Therapeutics, Inc.